Key points from article :
San Diego-based Alida Biosciences, founded in 2020, secured $7.5 million in Series A funding to advance its innovative tools for analyzing multiple RNA modifications simultaneously.
Their newly launched EpiPlex kit and EpiScout software streamline the complex process of epitranscriptomic analysis, even with limited RNA samples, like those from biopsies.
This technology holds promise for aging research, as changes in RNA modifications are linked to various age-related diseases.
Early testing at the Fred Hutchinson Cancer Research Center has been positive, with researchers praising the kit's ease of use and efficiency.
Led by Genoa Ventures, the funding round, combined with $4 million in grants from the National Human Genome Research Institute, will bolster AlidaBio's product development in this burgeoning field.
